Dash Bio, a pioneering company in the bioanalysis sector, has successfully secured an additional $11 million in funding, elevating its total capital raised to $17.5 million. This funding round was led by The Aligned Fund, with participation from several other investors including Freestyle Capital, Cybernetix Ventures, and Swift Ventures. The announcement was made on July 23, 2025, from the company’s headquarters in Newton, Massachusetts.
The funds will be directed towards enhancing Dash Bio’s fully automated, Good Laboratory Practice (GLP)-compliant bioanalysis platform, which aims to reshape drug development processes. Dash Bio is addressing a critical issue in the biotech industry: the lengthy and costly journey of drug development, which can span from 7 to 12 years and often involves outsourcing over 70% of development work to contract research organizations (CROs). These outsourced services are often inefficient and misaligned with the industry’s increasing demand for speed.
By leveraging advanced technology, including robotics and artificial intelligence, Dash Bio is poised to revolutionize the industry. The company’s platform can deliver assays such as ELISA, LC-MS, and qPCR at speeds up to 10 times faster than traditional providers. This capability allows drug developers to move more swiftly from initial concept to Investigational New Drug (IND) application and ultimately to regulatory approval.
“Our mission at Dash is to address the broken state of drug development, which poses one of the greatest challenges to progress in biotechnology,” stated Dave Johnson, co-founder and CEO of Dash Bio. Johnson, who previously served as Chief Data & AI Officer at Moderna, emphasized that the platform was designed from the ground up to integrate real automation with scientific rigor. He added, “This funding is a strong signal that the industry is ready to embrace a new standard—one where bioanalysis acts as a catalyst rather than a constraint.”
Dash Bio’s innovative approach is gaining traction within the industry. Since its initial fundraising efforts, the company has attracted several top-tier biopharma companies as clients and has assembled a team of experts drawn from leading organizations, including Moderna and Science Exchange. This team combines extensive knowledge in bioanalysis, software engineering, and laboratory automation, positioning Dash Bio to introduce industrial-grade efficiency into drug development.
According to Ariel Winton-Jones, Partner at The Aligned Fund, “Dash Bio isn’t just faster—it’s foundational. Their team has built the kind of tech-forward infrastructure that biotech has needed for years.” Winton-Jones underscored the belief that Dash is creating a new standard for bioanalysis that will extend beyond current applications.
The newly acquired funding will support Dash Bio in scaling its automated platform, expanding its range of assays, and investing in proprietary sample and assay management software. The company aims to onboard new clients across various stages of drug development, from preclinical to late-stage clinical trials.
Founded with the goal of accelerating clinical development, Dash Bio combines state-of-the-art technology with a commitment to delivering high-quality bioanalysis at unprecedented speeds. By integrating robotics and AI into its operations, the company is helping biopharma teams expedite the delivery of therapies to patients, thereby addressing a critical need in the healthcare landscape.
For more information, visit Dash Bio’s website at www.dash.bio.